|[March 07, 2014]
Research and Markets: Adult and Adolescent Vaccines Market to 2018 - Pharmaceutical Giants GSK and Merck Are Fighting It Out
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/5kqpfs/adult_and)
has announced the addition of the "Adult
and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in
Late-Stage Development and Prevnar Approval for Use in Adults to Drive
Growth" report to their offering.
Protection from Cervical Cancer Hindered by Market Rivalry
Pharmaceutical giants GlaxoSmithKline (GSK) and Merck are fighting it
out in the vaccination market, as countries pick sides in their cervical
cancer vaccination programs.
This new shows that existing cervical cancer vaccines, GSK's Cervarix
and Merck's Gardasil, are competing against each other for valuable
market share in a highly rewarding market segment.
The global vaccines market is highly fragmented, and national health
authorities can have dramatically differing requirements and
regulations, delaying the introduction of some vaccines across global
markets. The inclusion of any vaccine into a national immunization
schedule promises widespread immunization coverage for the population,
and increases the potential for huge revenues for the company.
Despite the European Commission approving Cervarix in 2007, the vaccine
ws only approved in the US two years later, resulting in a monopoly for
competing vaccine Gardasil in the US during this period. Gardasil has
also now been approved for use in men to prevent genital warts and anal
cancer caused due to human papillomavirus infection, providing the drug
with a further strength against competing products.
Cervical cancer vaccines are essentially prophylactic vaccines that
prevent against the infection of HPV, which is responsible for 70% of
cervical cancer cases in women. HPV vaccines have been found to reduce
the incidence of cervical cancer, an area with a high disease burden,
and various countries are consequently offering vaccinations for all
young girls as a widespread preventative measure. In addition to this,
the Advisory Committee on Immunization Practices (ACIP) now also
recommends that all 11-12 year old males get vaccinated against HPV, as
this will decrease the risk for male genital warts, and reduce the
potential for HPV transmission in the future.
Various other high-burden diseases are still urgently in need of
vaccines, with HIV/AIDS, malaria and tuberculosis representing some of
the most pressing health concerns of many governments across the world.
HPV vaccines may herald a new era of preventative medicine, as major
diseases are stopped before they ever start.
The Human Papillomavirus (HPV) vaccines market for adults and
adolescents across the US, Germany, Spain, Italy, France, the UK and
Japan is expected to grow from a strong value of US$1.8 billion in 2011
to US$2.2 billion in 2018. Revenue from HPV vaccines peaked in 2008,
following the initiation of nationwide immunization programs, but the
anticipated treatment of all children and the high cost of HPV
vaccinations, at over US$100 per person, secures this market's future.
Key Topics Covered:
1 Table of Contents
4 Market Characterization and Forecast
5 Influenza Vaccines
6 Tetanus, Diphtheria and Pertussis Vaccines
7 Pneumococcal Vaccines
8 Meningococcal Vaccines
9 Human Papilloma Virus Vaccines
10 Hepatitis Vaccines
11 Measles, Mumps and Rubella Vaccines
12 Zoster Vaccines
13 Varicella Vaccines
14 Competitive Landscape
15 Strategic Consolidations
For more information visit http://www.researchandmarkets.com/research/5kqpfs/adult_and
[ InfoTech Spotlight's Homepage ]